Iterum Therapeutics (NASDAQ:ITRM) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Iterum Therapeutics (NASDAQ:ITRM) in a report released on Friday, Benzinga reports. They currently have a $6.00 price target on the stock.

Iterum Therapeutics Stock Performance

Shares of ITRM opened at $1.24 on Friday. The company has a debt-to-equity ratio of 3.63, a current ratio of 1.07 and a quick ratio of 1.07. Iterum Therapeutics has a one year low of $0.62 and a one year high of $2.50. The firm has a market capitalization of $20.53 million, a P/E ratio of -0.47 and a beta of 2.29. The business has a fifty day moving average of $1.42 and a 200 day moving average of $1.57.

Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.11. As a group, sell-side analysts anticipate that Iterum Therapeutics will post -1.76 EPS for the current year.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.